Twitter-Delivered CME/CE on
Chronic Kidney Disease from @ckd_ce

The need for consistent updates and agile content is imperative for today’s clinician to remain current on the continuum of scientific data. This is particularly important in the care of patients with or at risk for CKD, as this has become a multidisciplinary and interprofessional focus.  Kidney health is now linked not only pathophysiologically but also by treatment strategies that target diverse cardiovascular outcomes as well as renal health. These issues are subject to frequent pivotal trial publications, guidelines updates, FDA action, and outcomes assessments.  

Our Tweetorials

Your new source for free CE/CME via Twitter!
Each program provides 0.5hr – 1.0hr credit for physicians, pharmacists, and nurses.

Why Being Nonsteroidal Matters

2) This series is supported by educational grants from AstraZeneca & Bayer, & is intended for healthcare professionals. Accreditation...

ADPKD: Case-Based Learning

2) Our #accredited #tweetorial series on #ADPKD is supported by an independent educational grant from Otsuka Pharmaceuticals and is intended for...

@CKD_CE on Twitter

Your only source for ACCREDITED SoMe-delivered

serialized professional cardiometabolic education. Physicians, nurses, pharmacists–come one, come all!

On Twitter at @ckd_ce, we present a series of tweetorials, Twitter-delivered case studies, and Twitter Journal Clubs, each accredited for 0.5hr – 1.0hr CE/CME.  Programs are presented by expert faculty in engaging and fully interactive format.  Our unique program harnesses the reach, up-to-the-minute currency, and accessibility of social media to deliver a constant flow of accredited, interactive, expert-delivered educational programs to a multidisciplinary and interprofessional audience of engaged clinicians.

Completed programs appear “unrolled” on this webpage, but to maximize the learning value of these innovative programs, please follow @ckd_ce.

Here is our article on kidney biomarkers @KIReports - “Kidney disease complexity manifested - one biomarker size does not fit all”.

We discuss about :
🧬 Ideal biomarker
🧬 Conventional biomarkers
🧬 Biomarkers in AKI
🧬 Biomarkers in CKD.

https://www.kireports.org/article/S2468-0249(22)01439-5/fulltext

📌#Empagliflozin Improves Outcomes in 👥 w/ Heart Failure & Preserved Ejection Fraction Irrespective of Age
#CardioEd #CardioTwitter #HFpEF

.@KatherineTuttl8 SGLT2 inhibitors, GLP1 receptor agonists, & non-steroidal MRAs along w/ a conventional ACE inhibitor or ARB are recommended therapies for persons w/ diabetes & CKD

#Nephpearls #HiD2022 #Cardiorenal

2
Load More...